Tabrecta
Payments companies reported to CMS as associated with Tabrecta. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Tabrecta, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Tabrecta
These are the largest totals companies reported as associated with Tabrecta. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Xiuning Le | Boston, MA | Internal Medicine | $4,387.50 |
| Joshua Sabari | New York, NY | Hematology & Oncology | $3,178.09 |
| Edgardo Santos | Fort Lauderdale, FL | Hematology & Oncology | $891.51 |
| Raja Mudad | Miami, FL | Hematology & Oncology | $711.04 |
| Mark Socinski | Orlando, FL | Hematology & Oncology | $675.00 |
| David Waterhouse | Cincinnati, OH | Hematology & Oncology | $675.00 |
| Jason Porter | Germantown, TN | Hematology & Oncology | $664.70 |
| Alexander Spira | Fairfax, VA | Medical Oncology | $525.00 |
| Martin Dietrich | Rockledge, FL | Hematology & Oncology | $525.00 |
| Sungwon Kyung | Los Angeles, CA | Hematology & Oncology | $294.68 |
Prescribed Tabrecta?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.